OMEICOS Advances Mitochondrial Disease Therapy with Promising Phase 2a Results
OMEICOS Therapeutics GmbH announced positive topline results from its Phase 2a PMD-OPTION study evaluating OMT-28, an orally available biased S1PR1 receptor modulator, in patients with primary mitochondrial diseases (PMD). The study suggests potential therapeutic benefits for patients with mitochondrial myopathy and cardiomyopathy, a rare group of genetic disorders characterized by impaired cellular energy production.
Trial Specifics
The open-label Phase 2a study enrolled 29 patients with primary mitochondrial diseases across nine expert sites in Germany, Italy, and The Netherlands. Participants received 24 mg of OMT-28 once daily for up to 24 weeks, following a 12-week untreated run-in period used as an integrated control.
The trial demonstrated a response rate exceeding 60%, with statistically significant improvements in functional tests including the 12-Minute Walk Test and 5x Sit-to-Stand Test. Notably, the study observed approximately 30% increases in NAD+ levels among responders and significant improvements in glutathione metabolism markers.
OMEICOS executives indicated the company will prepare for a potentially pivotal Phase 2b/3 study, with readiness anticipated in the second half of 2026.
Research Context
OMT-28 operates through a novel mechanism targeting the Sphingosine-1-Phosphate Receptor 1 (S1PR1) and activating mitochondrial sirtuins SIRT1 and SIRT3. These molecular targets are critical in regulating mitochondrial metabolism, reducing oxidative stress, and improving cellular energy production.
Primary mitochondrial diseases represent a challenging therapeutic landscape, characterized by genetic heterogeneity and limited treatment options. Current management remains largely supportive, with no approved disease-modifying therapies for most PMD subtypes.
Competitive Landscape
While several S1PR1 modulators exist in multiple sclerosis and inflammatory conditions—such as ozanimod (Bristol Myers Squibb) and siponimod (Novartis)—OMT-28 represents a potentially differentiated approach specifically targeting mitochondrial dysfunction.
Other investigational therapies in the mitochondrial disease space include EPI-743 (Edison Pharmaceuticals) and idebenone (Santhera Pharmaceuticals), highlighting the growing interest in addressing these complex genetic disorders.
The research suggests OMT-28 could offer a promising therapeutic strategy, though further clinical validation remains necessary to establish its long-term efficacy and safety profile.
Spot something wrong? Report an issue with this article